Stemcell Technologies, Inc. wholesales medical and hospital equipment. Its products include cell culture media and supplements, cell isolation products, primary and cultured cells, cell storage media, matrices and substrates, and cytokines. The firm offers contact assay services, custom solutions, product and scientific support, standardization tools, training programs, and science communication services. The company was founded by Allen Eaves in 1993 and is headquartered in Tukwila, WA.

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners.

Kangfang Pharmaceutical Co., Ltd., established on 2017-08-10, Business scope includes medical research and experimental development;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product sales(No licensed chemical products);pharmaceutical production;Drug Wholesale;Drug import and export;Import and export;Technology Import and Export

The company has built a global level of bio-pharmaceutical research and development and industrialization platform; established for cancer, autoimmune diseases, inflammation and cardiovascular disease of the rich product line. The scale of the company's platform, hardware and software facilities, the number of new drug product lines, R & D team in the country are the same industry-leading level. Kang Fang biological has been with the international and domestic listed pharmaceutical companies to establish a cooperative relationship, the joint development of innovative antibodies to new drugs, is a strategic cooperation in the form of development of new drugs in the forerunner.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

KS Biomedix Holdings is a company that develops pharmaceutical products and provide consulting services.

STCube, Inc. engages in the development and distribution of information technology (IT) services. It operates through the following divisions: IT, Robot, and Bio Technology. The IT division provides robots for personal services, application solutions, and cleaner. The Robot division supplies robot control module and vision board for aircons. The Bio Technology division offers medicines for cancer. The company was founded on August 16, 1989 and is headquartered in Seoul, South Korea.

Huabo Biomedical Technology (Shanghai) Co., Ltd., established on 2011-06-02, The scope of business includes the development of biotechnology,biopharmaceuticals,R&D and technology transfer of vaccine products,Research and development of biological reagents for non-clinical diagnosis,Sales,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Pasteur Sanofi Diagnostics, part of Bio-Rad Laboratories, Inc., is a company headquartered in France that develops and manufactures clinical diagnostic kits.

Shanghai Novamab Biopharmaceuticals Co., Ltd. is a company headquartered in Shanghai, China. The firm provides scientific research and development services. It was founded in 2017 by Ya Kun Wan, who has been the CEO since that date.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

STEMCELL Technologies Inc. is a Canadian biotechnology company that develops specialty cell culture media, cell isolation systems and accessory products for life science research. Driven by science and a passion for quality, STEMCELL supports the advancement of scientific research around the world with our catalogue of more than 2000 cell biology research tools. STEMCELL Technologies was launched in 1993 when founder and CEO Allen Eaves needed a way to meet the increasing demands for his standardized, cost-effective cell culture media for growing blood-forming stem cells. At the time, Eaves was a hematologist and cancer researcher heading the Terry Fox Laboratories (TFL) and head of clinical hematology at the University of British Columbia in Vancouver, Canada. Unsatisfied with commercially available cell culture reagents, Eaves’ research group at the TFL began making their own hematopoietic stem cell culture media using the highest quality materials they could find. Colleagues also wanted to use this media, and Eaves was able to supplement his research funds by selling culture media to other lab groups. Eventually the demand for the media from researchers around the world warranted building a designated clean room for production. The TFL did not have the funding and instead, Eaves was encouraged to purchase the business and create an independent company. Mortgaging his house and receiving a loan from Western Economic Diversification, Eaves was able to build a clean room and STEMCELL Technologies Inc. was born on July 2, 1993. STEMCELL has become the largest biotech company in Canada and continues to reinvest all profits back into developing products to better support the international research community. As of 2016, the company employs more than 800 people globally, with over one-third of those holding a PhD or MSc, and the majority of employees having a BSc or Engineering degree. A large number of the company’s employees are located in Vancouver, Canada with additional employees and facilities in 11 other countries.

Shenzhen Megaray Biotechnology Co., Ltd., established on 2019-04-03, Business scope includes general business items:Engaged in technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer.cosmetic,daily necessities,Chemical Products(Removal of hazardous chemicals),Instrumentation,rubber products,Glass product,chemical reagent(Removal of hazardous chemicals)promotion of.,The licensing program is:

Beijing Nuanbo Biotechnology Co., Ltd., established on 2019-09-11, Business scope includes technology development,transfer,to promote,Serve,consult;software development;Computer System Services.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Trustees of Dartmouth College, part of Dartmouth College, is a company headquartered in Hanover, NH. The firm operates higher education institutes. It was founded in 1769.